Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 11;11(6):973.
doi: 10.3390/cells11060973.

Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer

Affiliations
Review

Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer

Md Zahirul Islam Khan et al. Cells. .

Abstract

Gastrointestinal cancers (GICs) remain the most diagnosed cancers and accounted for the highest cancer-related death globally. The prognosis and treatment outcomes of many GICs are poor because most of the cases are diagnosed in advanced metastatic stages. This is primarily attributed to the deficiency of effective and reliable early diagnostic biomarkers. The existing biomarkers for GICs diagnosis exhibited inadequate specificity and sensitivity. To improve the early diagnosis of GICs, biomarkers with higher specificity and sensitivity are warranted. Proteomics study and its functional analysis focus on elucidating physiological and biological functions of unknown or annotated proteins and deciphering cellular mechanisms at molecular levels. In addition, quantitative analysis of translational proteomics is a promising approach in enhancing the early identification and proper management of GICs. In this review, we focus on the advances in mass spectrometry along with the quantitative and functional analysis of proteomics data that contributes to the establishment of biomarkers for GICs including, colorectal, gastric, hepatocellular, pancreatic, and esophageal cancer. We also discuss the future challenges in the validation of proteomics-based biomarkers for their translation into clinics.

Keywords: biomarkers; gastrointestinal cancer; mass spectrometry; multi-omics; proteomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Types of cancer biomarkers. Biomarkers are mostly found in body fluids including blood, urine, saliva, and also in cancer tissues. Cancer biomarkers belong to a variety of biological elements such as DNA, mRNAs, proteins, long non-coding RNAs (lncRNAs), miRNAs, exosomes, cellular metabolites, and organic materials. This figure was based on a published article by Wu et al. (2015) [9].
Figure 2
Figure 2
A typical workflow of bottom-up mass spectrometry. Proteins are collected from patients or experiments, and then chemically or enzymatically digested for conversion into the mixture of peptides. The peptides are then ready for mass spectrometry instrumentation and separated into a spectrum according to the mass value. Finally, the proteins are analyzed by using database search or computation analysis.

Similar articles

Cited by

References

    1. Henry N.L., Hayes D.F. Cancer biomarkers. Mol. Oncol. 2012;6:140–146. doi: 10.1016/j.molonc.2012.01.010. - DOI - PMC - PubMed
    1. Chatterjee S.K., Zetter B.R. Cancer biomarkers: Knowing the present and predicting the future. Future Oncol. 2005;1:37–50. doi: 10.1517/14796694.1.1.37. - DOI - PubMed
    1. Liu D. Cancer biomarkers for targeted therapy. Biomark. Res. 2019;7:25–27. doi: 10.1186/s40364-019-0178-7. - DOI - PMC - PubMed
    1. Dobbin K.K., Cesano A., Alvarez J., Hawtin R., Janetzki S., Kirsch I., Masucci G.V., Robbins P.B., Selvan S.R., Streicher H.Z., et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II—Clinical validation and regulatory considerations. J. Immunother. Cancer. 2016;4:77. doi: 10.1186/s40425-016-0179-0. - DOI - PMC - PubMed
    1. Goossens N., Nakagawa S., Sun X., Hoshida Y. Cancer biomarker discovery and validation. Transl. Cancer Res. 2015;4:256–269. doi: 10.3978/j.issn.2218-676x.2015.06.04. - DOI - PMC - PubMed

Publication types

LinkOut - more resources